BACKGROUND & AIMS: The Toll-like receptor (TLR) 4 mediates homeostasis of the intestinal epithelial cell (IEC) barrier. We investigated the effects of TLR4-D299G on IEC functions. METHODS: We engineered IECs (Caco-2) to stably overexpress hemagglutinin-tagged wild-type TLR4, TLR4-D299G, or TLR4-T399I. We performed gene expression profiling using DNA microarray analysis. Findings were confirmed by real-time, quantitative, reverse-transcriptase polymerase chain reaction, immunoblot, enzyme-linked immunosorbent assay, confocal immunofluorescence, and functional analyses. Tumorigenicity was tested using the CD1 nu/nu mice xenograft model. Human colon cancer specimens (N = 214) were genotyped and assessed for disease stage. RESULTS: Caco-2 cells that expressed TLR4-D299G underwent the epithelial-mesenchymal transition and morphologic changes associated with tumor progression, whereas cells that expressed wild-type TLR4 or TLR4-T399I did not. Caco-2 cells that expressed TLR4-D299G had significant increases in expression levels of genes and proteins associated with inflammation and/or tumorigenesis compared with cells that expressed other forms of TLR4. The invasive activity of TLR4-D299G Caco-2 cells required Wnt-dependent activation of STAT3. In mice, intestinal xenograft tumors grew from Caco-2 cells that expressed TLR4-D299G, but not cells that expressed other forms of TLR4; tumor growth was blocked by a specific inhibitor of STAT3. Human colon adenocarcinomas from patients with TLR4-D299G were more frequently of an advanced stage (International Union Against Cancer [UICC] ≥III, 70% vs 46%; P = .0142) with metastasis (UICC IV, 42% vs 19%; P = .0065) than those with wild-type TLR4. Expression of STAT3 messenger RNA was higher among colonic adenocarcinomas with TLR4-D299G than those with wild-type TLR4. CONCLUSIONS: TLR4-D299G induces features of neoplastic progression in intestinal epithelial Caco-2 cells and associates with aggressive colon cancer in humans, implying a novel link between aberrant innate immunity and colonic cancerogenesis.
BACKGROUND & AIMS: The Toll-like receptor (TLR) 4 mediates homeostasis of the intestinal epithelial cell (IEC) barrier. We investigated the effects of TLR4-D299G on IEC functions. METHODS: We engineered IECs (Caco-2) to stably overexpress hemagglutinin-tagged wild-type TLR4, TLR4-D299G, or TLR4-T399I. We performed gene expression profiling using DNA microarray analysis. Findings were confirmed by real-time, quantitative, reverse-transcriptase polymerase chain reaction, immunoblot, enzyme-linked immunosorbent assay, confocal immunofluorescence, and functional analyses. Tumorigenicity was tested using the CD1 nu/nu mice xenograft model. Humancolon cancer specimens (N = 214) were genotyped and assessed for disease stage. RESULTS:Caco-2 cells that expressed TLR4-D299G underwent the epithelial-mesenchymal transition and morphologic changes associated with tumor progression, whereas cells that expressed wild-type TLR4 or TLR4-T399I did not. Caco-2 cells that expressed TLR4-D299G had significant increases in expression levels of genes and proteins associated with inflammation and/or tumorigenesis compared with cells that expressed other forms of TLR4. The invasive activity of TLR4-D299G Caco-2 cells required Wnt-dependent activation of STAT3. In mice, intestinal xenograft tumors grew from Caco-2 cells that expressed TLR4-D299G, but not cells that expressed other forms of TLR4; tumor growth was blocked by a specific inhibitor of STAT3. Humancolon adenocarcinomas from patients with TLR4-D299G were more frequently of an advanced stage (International Union Against Cancer [UICC] ≥III, 70% vs 46%; P = .0142) with metastasis (UICC IV, 42% vs 19%; P = .0065) than those with wild-type TLR4. Expression of STAT3 messenger RNA was higher among colonic adenocarcinomas with TLR4-D299G than those with wild-type TLR4. CONCLUSIONS:TLR4-D299G induces features of neoplastic progression in intestinal epithelial Caco-2 cells and associates with aggressive colon cancer in humans, implying a novel link between aberrant innate immunity and colonic cancerogenesis.
Authors: N C Arbour; E Lorenz; B C Schutte; J Zabner; J N Kline; M Jones; K Frees; J L Watt; D A Schwartz Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: Prasad Rallabhandi; Jessica Bell; Marina S Boukhvalova; Andrei Medvedev; Eva Lorenz; Moshe Arditi; Val G Hemming; Jorge C G Blanco; David M Segal; Stefanie N Vogel Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: Michael V Dubina; Nikolay A Iatckii; Dimitrii E Popov; Sergei V Vasil'ev; Vladimir A Krutovskikh Journal: Oncogene Date: 2002-07-25 Impact factor: 9.867
Authors: K K Gkouskou; M Ioannou; G A Pavlopoulos; K Georgila; A Siganou; G Nikolaidis; D C Kanellis; S Moore; K A Papadakis; D Kardassis; I Iliopoulos; F A McDyer; E Drakos; A G Eliopoulos Journal: Oncogene Date: 2015-08-17 Impact factor: 9.867
Authors: Magdalena Frank; Eva Maria Hennenberg; Annette Eyking; Michael Rünzi; Guido Gerken; Paul Scott; Julian Parkhill; Alan W Walker; Elke Cario Journal: J Immunol Date: 2015-01-14 Impact factor: 5.422
Authors: Kwang Hwa Jung; Wonbeak Yoo; Heather L Stevenson; Dipti Deshpande; Hong Shen; Mihai Gagea; Suk-Young Yoo; Jing Wang; T Kris Eckols; Uddalak Bharadwaj; David J Tweardy; Laura Beretta Journal: Clin Cancer Res Date: 2017-05-22 Impact factor: 12.531
Authors: Ann M Janowski; Oscar R Colegio; Emma E Hornick; Jennifer M McNiff; Matthew D Martin; Vladimir P Badovinac; Lyse A Norian; Weizhou Zhang; Suzanne L Cassel; Fayyaz S Sutterwala Journal: J Clin Invest Date: 2016-09-12 Impact factor: 14.808